vs
Guardant Health, Inc.（GH）与PROVIDENT FINANCIAL SERVICES INC（PFS）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是PROVIDENT FINANCIAL SERVICES INC的1.2倍（$281.3M vs $225.2M），PROVIDENT FINANCIAL SERVICES INC净利率更高（35.3% vs -45.7%，领先80.9%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 17.3%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
PNC金融服务集团是总部位于美国宾夕法尼亚州匹兹堡的银行控股及金融服务企业，旗下银行子公司PNC银行业务覆盖美国27个州和华盛顿特区，拥有2629家营业网点与9523台ATM机，是美国资产规模、网点数量、存款规模、ATM保有量均位居前列的大型银行机构。
GH vs PFS — 直观对比
营收规模更大
GH
是对方的1.2倍
$225.2M
净利率更高
PFS
高出80.9%
-45.7%
两年增速更快
GH
近两年复合增速
17.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $225.2M |
| 净利润 | $-128.5M | $79.4M |
| 毛利率 | 64.6% | — |
| 营业利润率 | -43.0% | — |
| 净利率 | -45.7% | 35.3% |
| 营收同比 | 39.4% | — |
| 净利润同比 | -15.8% | 24.0% |
| 每股收益（稀释后） | $-1.01 | $0.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHPFS
| Q1 26 | — | $225.2M | ||
| Q4 25 | $281.3M | $225.7M | ||
| Q3 25 | $265.2M | $221.8M | ||
| Q2 25 | $232.1M | $214.2M | ||
| Q1 25 | $203.5M | $208.8M | ||
| Q4 24 | $201.8M | $205.9M | ||
| Q3 24 | $191.5M | $210.6M | ||
| Q2 24 | $177.2M | $163.8M |
净利润GHPFS
| Q1 26 | — | $79.4M | ||
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $71.7M | ||
| Q2 25 | $-99.9M | $72.0M | ||
| Q1 25 | $-95.2M | $64.0M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $46.4M | ||
| Q2 24 | $-102.6M | $-11.5M |
毛利率GHPFS
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
营业利润率GHPFS
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | 49.7% | ||
| Q3 25 | -37.3% | 45.8% | ||
| Q2 25 | -45.9% | 47.8% | ||
| Q1 25 | -54.6% | 44.0% | ||
| Q4 24 | -62.4% | 30.5% | ||
| Q3 24 | -61.3% | 31.0% | ||
| Q2 24 | -56.8% | -13.0% |
净利率GHPFS
| Q1 26 | — | 35.3% | ||
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 32.3% | ||
| Q2 25 | -43.0% | 33.6% | ||
| Q1 25 | -46.8% | 30.7% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 22.0% | ||
| Q2 24 | -57.9% | -7.0% |
每股收益（稀释后）GHPFS
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-1.01 | $0.64 | ||
| Q3 25 | $-0.74 | $0.55 | ||
| Q2 25 | $-0.80 | $0.55 | ||
| Q1 25 | $-0.77 | $0.49 | ||
| Q4 24 | $-0.90 | $0.37 | ||
| Q3 24 | $-0.88 | $0.36 | ||
| Q2 24 | $-0.84 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $222.1M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $2.9B |
| 总资产 | $2.0B | $25.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHPFS
| Q1 26 | — | $222.1M | ||
| Q4 25 | $378.2M | $209.1M | ||
| Q3 25 | $580.0M | $299.2M | ||
| Q2 25 | $629.1M | $258.0M | ||
| Q1 25 | $698.6M | $234.1M | ||
| Q4 24 | $525.5M | $205.9M | ||
| Q3 24 | $585.0M | $244.0M | ||
| Q2 24 | $933.7M | $290.5M |
总债务GHPFS
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益GHPFS
| Q1 26 | — | $2.9B | ||
| Q4 25 | $-99.3M | $2.8B | ||
| Q3 25 | $-354.5M | $2.8B | ||
| Q2 25 | $-305.5M | $2.7B | ||
| Q1 25 | $-250.8M | $2.7B | ||
| Q4 24 | $-139.6M | $2.6B | ||
| Q3 24 | $-60.1M | $2.6B | ||
| Q2 24 | $-1.6M | $2.6B |
总资产GHPFS
| Q1 26 | — | $25.2B | ||
| Q4 25 | $2.0B | $25.0B | ||
| Q3 25 | $1.3B | $24.8B | ||
| Q2 25 | $1.3B | $24.5B | ||
| Q1 25 | $1.3B | $24.2B | ||
| Q4 24 | $1.5B | $24.1B | ||
| Q3 24 | $1.5B | $24.0B | ||
| Q2 24 | $1.6B | $24.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | — |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHPFS
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $442.3M | ||
| Q3 25 | $-35.4M | $98.0M | ||
| Q2 25 | $-60.3M | $186.8M | ||
| Q1 25 | $-62.7M | $88.5M | ||
| Q4 24 | $-64.5M | $426.4M | ||
| Q3 24 | $-51.1M | $69.2M | ||
| Q2 24 | $-94.0M | $76.5M |
自由现金流GHPFS
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $430.7M | ||
| Q3 25 | $-45.8M | $96.7M | ||
| Q2 25 | $-65.9M | $182.6M | ||
| Q1 25 | $-67.1M | $87.4M | ||
| Q4 24 | $-83.4M | $425.1M | ||
| Q3 24 | $-55.3M | $67.9M | ||
| Q2 24 | $-99.1M | $75.5M |
自由现金流率GHPFS
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 190.8% | ||
| Q3 25 | -17.3% | 43.6% | ||
| Q2 25 | -28.4% | 85.2% | ||
| Q1 25 | -33.0% | 41.9% | ||
| Q4 24 | -41.3% | 206.4% | ||
| Q3 24 | -28.9% | 32.2% | ||
| Q2 24 | -55.9% | 46.1% |
资本支出强度GHPFS
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 5.1% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 2.4% | 2.0% | ||
| Q1 25 | 2.2% | 0.5% | ||
| Q4 24 | 9.4% | 0.6% | ||
| Q3 24 | 2.2% | 0.6% | ||
| Q2 24 | 2.9% | 0.6% |
现金转化率GHPFS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 2.59× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PFS
| Net Interest Income | $193.7M | 86% |
| Noninterest Income | $31.5M | 14% |
